肠道微生物影响结直肠癌化疗疗效的研究现状

doi:10.11904/j.issn.1002-3070.2021.05.017

Abstract

Abstract: Gut microbes are an “ecosystem” closely related to body health.On the one hand,intestinal microbes can provide nutrients for the body,participate in the body's metabolism and immune regulation,resist pathogens,and exert biological barrier functions.On the other hand,intestinal microbes and their metabolites can participate in the occurrence of colorectal cancer,regulate the mechanism of chemotherapy drugs and immune checkpoint inhibitors,then affect the efficacy of chemotherapy and immunotherapy,and regulate related adverse reactions.Based on a large number of previous studies on intestinal microbes and related literatures,this article will review the current status of intestinal microbes affecting the mechanism and efficacy of chemotherapy drugs for colorectal cancer,which is expected to be a new target for improving the treatment of colorectal cancer and reducing the side reaction of the drug toxicity.

Key words: Gut microbes, Colorectal cancer, Mechanism of drug action, Efficacy

CLC Number:

R730.1

HAN Shuling, YAO Yang, LIU Chao, ZHANG Yanqiao. Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer[J]. Journal of Practical Oncology, 2021, 35(5): 476-479.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/476

References

1 Peters BA,Dominianni C,Shapiro JA,et al.The gut microbiota in conventional and serrated precursors of colorectal cancer[J].Microbiome,2016,4(1):69.
2 Ma W,Mao Q,Xia W,et al.Gut microbiota shapes the efficiency of cancer therapy[J].Front Microbiol,2019,10:1050.
3 Hakim H,Dallas R,Wolf J,et al.Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia[J].Clin Infect Dis,2018,67(4):541-548.
4 Scott TA,Quintaneiro LM,Norvaisas P,et al.Host-microbe co-metabolism dictates cancer drug efficacy in C.elegans[J].Cell,2017,169(3):442-456.
5 Degnan PH,Taga ME,Goodman AL.Vitamin B12 as a modulator of gut microbial ecology[J].Cell Metab,2014,20(5):769-778.
6 梁敏.腹腔化疗对直肠癌根治术患者术后早期痛觉敏感性的影响及干预措施研究[D].济南:山东大学,2017.
7 Iida N,Dzutsev A,Stewart CA,et al.Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science,2013,342(6161):967-970.
8 Firwana B,Avaritt N,Shields B,et al.Do checkpoint inhibitors rely on gut microbiota to fight cancer?[J].J Oncol Pharm Pract,2017,24(6):468-472.
9 肖兴鹏.益生菌修复Cr(Ⅵ)和化疗药物奥沙利铂引起的机体损伤和肠道微生物紊乱[D].兰州:兰州大学,2017.
10 Alfredo PP,Jairo PS,Kyle KP,et al.Frontline Science:Microbiota reconstitution restores intestinal integrity after cisplatin therapy[J].J Leukoc Biol,2018,103(5):799-805.
11 Tsuchihashi Y,Abe S,Miyamoto L,et al.Novel hydrophilic camptothecin derivatives conjugated to branched glycerol trimer suppress tumor growth without causing diarrhea in murine xenograft models of human lung cancer[J].Mol Pharm,2020,17(4):1049-1058.
12 Stringer AM,Gibson RJ,Bowen JM,et al.Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile[J].Int J Exp Pathol,2009,90(5):489-499.
13 Stringer AM,Gibson RJ,Logan RM,et al.Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats[J].Cancer Biol Ther,2008,7(12):1919-1925.
14 Lin XB,Dieleman LA,Ali K,et al.Irinotecan(CPT-11)chemotherapy alters intestinal microbiota in tumour bearing rats[J].PLoS One,2012,7(7):e39764.
15 Han SW,Yang X,Pan YF,et al.Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer[J].Microb Pathog,2020,149:104343.
16 姚逸尘.肠道菌群与西妥昔单抗治疗晚期结直肠癌所致皮疹相关性研究[D].福州:福建医科大学,2019.
17 Topalian SL,Taube JM,Anders RA,et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J].Nat Rev Cancer,2016,16(5):275.
18 Yadav M,Jhunjhunwala S,Phung QT,et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature,2014,515(7528):572-576.
19 Le DT,Uram JN,Wang H,et al.PD-1 Blockade in Tumors with mismatch-repair deficiency[J].N Engl J Med,2015,372:2509-2520.
20 Santarpia M,Karachaliou N.Tumor immune microenvironment characterization and response to anti-PD-1 therapy[J].Cancer Biol Med,2015,12(2):74-78.
21 Goubet AG,Daillère R,Routy B,et al.The impact of the intestinal microbiota in therapeutic responses against cancer[J].C R Biol,2018,341(5):284-289.
22 Elkrief A,Derosa L,Zitvogel L,et al.The intimate relationship between gut microbiota and cancer immunotherapy[J].Gut Microbes,2019,10(3):424-426.
23 Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science,2015,350:1084-1089.
24 Rescigno M.A 'fit' microbiota to potentiate cancer immunotherapy[J].Genome Med,2015,7(1):1-2.
25 West N,Powrie F.Immunotherapy not working? check your microbiota[J].Cancer Cell,2015,28(6):687-689.
26 Routy B,Gopalakrishnan V,Daillere R,et al.The gut microbiota influences anticancer immunosurveillance and general health[J].Nat Rev Clin Oncol,2018,15(6):382-396.

[1]	HUANG Rui, LIU Chao, ZHANG Yanqiao. A systematic review of simvastatin in the treatment of colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(4): 365-369.
[2]	LIU Wen, QIAO Wenbo. Clinical research status of programmed cell death protein-1 and its ligand in colorectal cancer [J]. Journal of Practical Oncology, 2021, 35(4): 370-375.
[3]	ZHU Gongjian, ZHU Yitong, DING Gaoheng, WANG Hongzong, DU Meixia, LIU Yuqin. Analysis for characteristics and trends of colorectal cancer in Gansu cancer registry areas,2009—2015 [J]. Journal of Practical Oncology, 2021, 35(3): 212-217.
[4]	GUO Piaoting, MIN Li, CHEN Jianjun, WANG Xin, NI Siyi. Salvianolic acid B regulates ROS to inhibit the proliferation and promote apoptosis in colorectal cancer HCT-116 cells [J]. Journal of Practical Oncology, 2020, 34(6): 504-510.
[5]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[6]	DONG Manku, JIANG Fuquan, LIN Haiguan, SUN Xiaomin, LIU Jingxin, HU Gang, YANG Jianwu. LncRNA BLACAT1 targeting LEMD1 promotes the proliferation and metastasis of colorectal cancer cells [J]. Journal of Practical Oncology, 2020, 34(5): 418-424.
[7]	SUN Xiaoyan, ZHANG Xiaoyan. Prognostic significance of lncRNA-SChLAP1 high-expression in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 425-429.
[8]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[9]	LI Hengzhen, ZHANG Yanqiao. Application progress of liquid biopsy in the diagnosis of colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(4): 357-361.
[10]	ZHU Xiaoyun,ZHANG Yaning,MA Biping. Trend analysis of the death level and the probability of early death caused by colorectal cancer in Jinshan district,Shanghai,1980—2018 [J]. Journal of Practical Oncology, 2020, 34(3): 198-202.
[11]	LU Xuemei,LI Yuntao,AN Jinhui,JI Guozhong. The mechanism of lysophosphatidic acid in the development of colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(3): 276-281.
[12]	LI Bin, FENG Baoheng, YIN Fuxia, SU Wei. Establishment of a colorectal cancer xenograft model to study the bacterial infection in the intestine of mice and the mechanism of decitabine combined with cisplatin chemotherapy [J]. Journal of Practical Oncology, 2020, 34(2): 163-168.
[13]	ZENG Li, ZHUANG Shutong, DING Shihua, CHEN Chong, JIAO Lu, SUN Dayong. Molecular mechanisms of long non-coding RNA AFAP1-AS1 regulating the proliferation of colorectal cancer cells by PTEN/p-AKT signaling pathway [J]. Journal of Practical Oncology, 2020, 34(1): 11-16.
[14]	LIAO Daixiang, ZHENG Bo, ZHANG Yanbin, YU Junhui. Expression of RRBP1 and RABEX-5 proteins in colorectal cancer and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2020, 34(1): 43-48.
[15]	ZHANG Jinglan, LIU Ruibao. Progress in local interventional therapy for colorectal cancer with liver metastasis [J]. Journal of Practical Oncology, 2020, 34(1): 79-82.

Research status of intestinal microbes affecting the efficacy of chemotherapy for colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments